Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KaraLiv
- Development stage
- Unknown
- Lead developer
- Karallief
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
KaraLiv is a proprietary herbal blend developed by Karallief, Inc., designed to support liver health and maintain healthy liver enzyme levels. The formulation consists of standardized extracts from six plants: *Momordica charantia* (bitter melon), *Phyllanthus niruri*, *Andrographis paniculata*, *Brassica rapa*, *Asparagus racemosus*, and *Zingiber officinale* (ginger). Clinical evidence from a randomized, double-blind, placebo-controlled trial indicates that a 1,000 mg daily dose significantly reduces levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) in individuals with mild to moderately elevated liver enzymes. It is marketed as a powdered ingredient for use in dietary supplements, functional foods, and beverages.
- Brand names
- KaraLiv
- Other names
- KaraLiv
02
Targets
ALPL (Tissue-nonspecific alkaline phosphatase)AST (Glutamate oxaloacetate transaminase 1)
Beyond the preview
Go deeper on KaraLiv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KaraLiv.